Diagnosis Disrupted: Visby Medical Ignites At-Home Healthcare Revolution with $65M for Groundbreaking STI Test

Visby Medical™ has secured up to $65 million in a landmark new financing round.
This war chest will accelerate the launch of its recently FDA-authorized, rapid at-home Women's Sexual Health PCR test.
The move, backed by powerhouse investors, signals a seismic shift towards empowering individuals with lab-accurate diagnostics in the privacy of their homes.

A new era of personal healthcare is dawning. Visby Medical™, a pioneer in rapid PCR diagnostics, today announced a monumental funding injection of up to $65 million, led by healthcare investment titan Catalio Capital Management. This crucial capital will catapult the launch of Visby’s game-changing at-home Women's Sexual Health Test, firmly establishing the company’s ambition to lead the charge in at-home testing⁷.

Imagine: laboratory-grade PCR accuracy, the gold standard in infectious disease testing, available not in a clinic, but in the palm of your hand, delivering results within 30 minutes via a smartphone app. This is the reality Visby Medical is delivering – a single-use, disposable diagnostic that shatters barriers to STI testing, offering unprecedented privacy, speed, and convenience. Upon positive results, users are seamlessly connected with telemedicine providers, ensuring immediate consultation and treatment.

This isn't just about technology; it's a paradigm shift. "This funding round will enable Visby to deliver on our vision of empowering consumers with reliable and lab-accurate health information from the comfort of their homes," declared Adam de la Zerda, PhD, Founder and CEO of Visby Medical. Catalio Capital Management, whose partner Isaac Ro joins Visby’s board as an observer, shares this conviction, hailing Visby’s solution as "a breakthrough moment for the diagnostics industry."

Further strengthening Visby’s operational prowess, Chuck Alpuche, a seasoned executive with deep expertise in manufacturing scale-up and cost efficiency, joins the board as an independent director. His role will be pivotal in making this revolutionary technology accessible to millions. As Visby Medical expands its platform beyond STIs and COVID-19/flu tests⁵, the promise of truly democratized healthcare, accurate and available anywhere, anytime, moves closer to reality. Learn more at visbymedical.com and about Catalio at catalio.com.

Diagnosis Disrupted: Visby Medical Ignites At-Home Healthcare Revolution with $65M for Groundbreaking STI Test

References

Stay Updated!